Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:10/20/2008

EAST SETAUKET, N.Y., Oct. 20 /PRNewswire-FirstCall/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT), announces the appointment of Mel Sorensen, M.D. to the company's Board of Directors.

Dr. Sorensen is currently Board Director, President and Chief Executive Officer of Ascenta Therapeutics. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development.

Trained as a medical oncologist, Dr. Sorensen has dedicated his career to clinical cancer research and cancer drug development. After completing his oncology fellowship at the Mayo Clinic, Rochester, MN in 1988, Dr. Sorensen spent seven years at the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). At CTEP, he managed collaborations between companies developing new anti-cancer agents and academic clinics and clinical cooperative groups. He had responsibility for over 40 research compounds.

Following NCI, Dr. Sorensen spent nearly eight years at large pharmaceutical companies in leadership roles in oncology clinical development and medical affairs. He established Bayer's first clinical oncology department and oversaw multiple clinical trials (Phase 1, 2 and 3) of novel agents. He subsequently joined GlaxoSmithKline (GSK) as Vice-President, Global Leader and North American Head of Clinical Development and Medical Affairs for Oncology, where he recruited a large team of physicians and scientists and led global clinical development of chemotherapeutic agents. While at GSK and Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, Nippon Kayaku, and Hoffmann-La Roche).

Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his leadership, in less than three years Ascenta was transformed from a 5-person start-up with a single preclinical program int
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
3. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
4. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
7. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
8. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
11. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Epic Sciences, Inc. ... develops novel diagnostics to personalize and advance the treatment ... Gregory T. Lucier as chairman of Epic,s ... CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins ... commercializes its circulating rare cell analysis platform with special ...
(Date:7/30/2014)... 2014 Connecticut Center for Advanced Technology, ... East Hartford, Conn., was awarded a Rural Business Enterprise ... project that will determine the feasibility of implementing an ... USDA Rural Development provided $53,000 for CCAT under the ... phase of the feasibility study in fiscal year 2014. ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel drug ... seed financing from friends and family investors. Proceeds from ... novel sustained-release product for ophthalmology. , "We are grateful ... to this important work," said Dr. Ken Mandell, Founder ... areas in which innovations in drug delivery have already ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology Technology:Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... historians, journalists and politicians, and has been recounted everywhere from ... forces used chemical weapons on Iraqis just after World War ... squared with the historical record, says R. M. Douglas, a ... the December issue of The Journal of Modern History ...
... at the University of East Anglia (UEA) could contribute ... agricultural waste to generate clean electricity. Published today ... National Academy of Sciences (PNAS), the researchers have ... some bacteria survive by ,breathing rocks,. The findings ...
... roadside bombs to freeway crashes. Traumatic injury, the leading cause ... the body,s natural blood-clotting process. In an effort to ... a new Case Western Reserve University biomedical engineering professor, and ... that show promise in halting internal and external bleeding. Their ...
Cached Biology Technology:Despite claims, UK did not gas Iraqis in the 1920s, new research finds 2Despite claims, UK did not gas Iraqis in the 1920s, new research finds 3Despite claims, UK did not gas Iraqis in the 1920s, new research finds 4'Rock-breathing' bacteria could generate electricity and clean up oil spills 2Researchers take the inside route to halt bleeding 2
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... treatment has been shown to relieve patients, pain. ... transmission between the peripheral and central nervous systems, ... Radiation Medicine, Chinese Academy of Medical Sciences, China ... dorsal root ganglia (DRG) to provide relief for ... 14.8, 29.6 MBq) were implanted separately into the ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... chemicals routinely added to consumer products from carpets to ... Health officials, however, are concerned that one class of ... more than reducing fire-related injuries and property damage. ... distributed in the environment as contaminants, and trace levels ...
... testing for adult-onset diseases, including cancer, is generally discouraged ... be helpful. Yet, many children of BRCA mutation ... years before preventive interventions are indicated. ... Clinical Oncology, describes the prevalence and experiences of parental ...
... PICK: Can cancer drugs combine forces? ... with a drug known as imatinib (Gleevec), which targets ... their disease returns, because BCR-ABL mutants emerge that are ... with a drug known as dasatinib (SPRYCEL), which targets ...
Cached Biology News:SRMs track fire retardants in humans and environment 2JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7
... Time-resolved microscopy is the ultimate tool ... subcellular structures. Its applications previously have been ... because microscope optics do not transmit in ... leader in fluorescence spectroscopy, introduces a filter-based ...
... clear dishes with stacking feature for easy storage. ... number, created to easily match Cornings product number. ... the old Sigma-Aldrich number (Z70,947-6) or contact customer ... surface Comp Dim: surface area 55 cm 2 ...
... Mixes are formulated for use in one-step ... Green. One-step QRT-PCR mixes offer a quick ... pipetting steps are minimised, making the protocol ... 2x ABsolute QRT-PCR Mix is supplied with ...
... and pathophysiological stressful conditions trigger the synthesis ... heat shock proteins (HSPs), more appropriately called ... Hsp90 family of proteins in mammalian cells ... and Trap-1 (Hsp75). It was found that ...
Biology Products: